Systematic review of antibiotic resistance in acne: An increasing topical and oral threat

The Lancet Infectious Diseases

Volumn 16, Issue 3, 2016, Pages e23-e33

  Walsh, Timothy R ^a   Efthimiou, John ^b   Dréno, Brigitte ^c  

^a Heath Hospital Cardiff   (United Kingdom)

^b Independent Consultant   (United Kingdom)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENZOYL PEROXIDE; RETINOID; ANTIINFECTIVE AGENT;

ACNE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CROSS RESISTANCE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EVIDENCE BASED PRACTICE; HUMAN; LONG TERM CARE; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; REVIEW; STEADY STATE; SYSTEMATIC REVIEW; TREATMENT DURATION; ACNE VULGARIS; DRUG EFFECTS; MICROBIOLOGY;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; DRUG RESISTANCE, BACTERIAL; HUMANS; PROPIONIBACTERIUM ACNES; RETINOIDS;

EID: 84959099459     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00527-7     Document Type: Review

References (119)

1. Patel M, Bowe WP, Heughebaert C, Shalita AR The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol 2010, 9:655-664.
2. Cooper AJ Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998, 169:259-261.
3. Eady AE, Cove JH, Layton AM Is antibiotic resistance in cutaneous propionibacteria clinically relevant?: implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003, 4:813-831.
4. Andriessen A, Lynde CW Antibiotic resistance: shifting the paradigm in topical acne treatment. J Drugs Dermatol 2014, 13:1358-1364.
5. Kraning KK, Odland GF Prevalence, morbidity, and cost of dermatological diseases. J Invest Dermatol 1979, 73:395-401.
6. Leyden JJ New understandings of the pathogenesis of acne. J Am Acad Dermatol 1995, 32:S15-S25.
7. Cunliffe WJ, Gould DJ Prevalence of facial acne vulgaris in late adolescence and in adults. BMJ 1979, 1:1109-1110.
8. Gollnick HP, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A Pathogenesis and pathogenesis related treatment of acne. J Dermatol 1991, 18:489-499.
9. Cunliffe WJ, Gollnick H Acne: diagnosis and management 2001, Martin Dunitz, London.
10. Plewig G, Kligman AM Acne and rosacea 2000, Springer-Verlag, New York, NY. 3rd edn.
11. Cunliffe WJ, Holland DB, Clark SM, Stables GI Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000, 142:1084-1091.
12. Cunliffe WJ, Simpson NB Disorders of the sebaceous gland. Textbook of Dermatology 1998, 1927-1984. Blackwell Science, Oxford. 6th edn. R.H. Champion, J.L. Burton, D.A. Burns, S.M. Breathnach (Eds.).
13. Burton JL, Shuster S The relationship between seborrhoea and acne vulgaris. Br J Dermatol 1971, 84:600-602.
14. Leyden JJ, McGinley KJ, Mills OH, Kligman AM Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 1975, 65:382-384.
15. Webster GF Inflammation in acne vulgaris. J Am Acad Dermatol 1995, 33:247-253.
16. Leyden JJ The evolving role of Propionibacterium acnes in acne. Semin Cutan Med Surg 2001, 20:139-143.
17. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009, 60(suppl):1-50.
18. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003, 139:459-464.
19. Toossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai-Asadi A Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol 2008, 7:1149-1152.
20. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002, 169:1535-1541.
21. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003, 49(suppl):S1-37.
22. Rosen T Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol 2011, 10:724-733.
23. Dréno B, Thiboutot D, Gollnick H, et al. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol 2014, 24:330-334.
24. Faghihi G, Isfahani AK, Hosseini SM, Radan MR Efficacy of intense pulsed light combined with topical erythromycin solution 2% versus topical erythromycin solution 2% alone in the treatment of persistent facial erythematous acne macules. Adv Biomed Res 2012, 1:70.
25. Abdel Fattah NS, Darwish YW In vitro antibiotic susceptibility patterns of Propionibacterium acnes isolated from acne patients: an Egyptian university hospital-based study. J Eur Acad Dermatol Venereol 2013, 27:1546-1551.
26. Dumont-Wallon G, Moyse D, Blouin E, Dréno B Bacterial resistance in French acne patients. Int J Dermatol 2010, 49:283-288.
27. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003, 148:467-478.
28. Clindamycin 150 mg capsules summary of product characteristics Sandoz Limited, (accessed Jan 11, 2016). http://www.medicines.org.uk/emc/medicine/21628.
29. Del Rosso JQ Topical therapy for acne in women: is there a role for clindamycin phosphate-benzoyl peroxide gel?. Cutis 2014, 94:177-182.
30. Kircik LH The role of benzoyl peroxide in the new treatment paradigm for acne. J Drugs Dermatol 2013, 12:s73-s76.
31. Zaenglein AL, Shamban A, Webster G, et al. A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris. J Drugs Dermatol 2013, 12:619-625.
32. Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012, 26(suppl 1):1-29.
33. Stratton CW Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003, 9:10-16.
34. Eady EA, Gloor M, Leyden JJ Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003, 206:54-56.
35. Del Rosso JQ, Kircik LH The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician?. J Drugs Dermatol 2013, 12(suppl):s109-s115.
36. Beylot C, Auffret N, Poli F, et al. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol 2014, 28:271-278.
37. Jugeau S, Tenaud I, Knol AC, et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol 2005, 153:1105-1113.
38. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
39. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
40. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010, 303:1707-1715.
41. Cigana C, Assael BM, Melotti P Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 2007, 51:975-981.
42. Martinez FJ, Curtis JL, Albert R Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008, 3:331-350.
43. Thiboutot D, Dreno B, Gollnick H, et al. A call to limit antibiotic use in acne. J Drugs Dermatol 2013, 12:1331-1332.
44. Jesitus J Dermatologists contribute to overuse of antibiotics. Dermatology Times Oct 1, 2013, (accessed Jan 11, 2016). http://dermatologytimes.modernmedicine.com/dermatology-times/news/dermatologists-contribute-overuse-antibiotics?page=full.
45. Clark C Antibiotic use for acne reducing effectiveness elsewhere, says leading dermatologist. Pharm J 2014, 293:7820-7821.
46. Lee YH, Liu G, Thiboutot DM, Leslie DL, Kirby JS A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: investigating practice gaps and potential cost-savings. J Am Acad Dermatol 2014, 71:70-76.
47. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014, 14:742-750.
48. Surveillance of antimicrobial consumption in Europe 2011 2014, European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control, Stockholm.
49. Antibiotic resistance-a threat to global health security WHO, (accessed Jan 11, 2016). http://www.who.int/drugresistance/activities/wha66_side_event/en/.
50. Chan M Antimicrobial resistance in the European Union and the world (accessed Jan 11, 2016). http://www.who.int/dg/speeches/2012/amr_20120314/en.
51. Davies SC Annual report of the Chief Medical Officer. Volume two, 2011. Infections and the rise of antimicrobial resistance 2013, Department of Health, London.
52. Antibiotic resistance threats in the United States, 2013 2013, Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
53. Walsh F Antibiotic resistance: Cameron warns of medical 'dark ages' (accessed Jan 11, 2016). http://www.bbc.co.uk/news/health-28098838.
54. Silver LL Challenges of antibacterial discovery. Clin Microbiol Rev 2011, 24:71-109.
55. Arias CA, Murray BE A new antibiotic and the evolution of resistance. N Engl J Med 2015, 372:1168-1170.
56. Bragginton EC, Piddock LJ UK and European Union public and charitable funding from 2008 to 2013 for bacteriology and antibiotic research in the UK: an observational study. Lancet Infect Dis 2014, 14:857-868.
57. UK Five year antimicrobial resistance strategy 2013 to 2018 2013, Department of Health, Department of Health, London.
58. Watts G UK declares war on antimicrobial resistance. Lancet 2014, 384:391.
59. Report to the president on combating antibiotic resistance Executive Office of the President and President's Council of Advisors on Science and Technology, (accessed Jan 11, 2016). https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf.
60. Antimicrobial espionage?. Lancet 2015, 385:746. The Lancet.
61. Nathan C, Cars O Antibiotic resistance-problems, progress, and prospects. N Engl J Med 2014, 371:1761-1763.
62. Das P, Horton R Antibiotics: achieving the balance between access and excess. Lancet 2016, 387:102-104.
63. Leyden JJ Antibiotic resistant acne. Cutis 1976, 17:593-596.
64. Crawford WW, Crawford IP, Stoughton RB, Cornell RC Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol 1979, 72:187-190.
65. Eady EA, Cove JH, Blake J, Holland KT, Cunliffe WJ Recalcitrant acne vulgaris. Clinical, biochemical and microbiological investigation of patients not responding to antibiotic treatment. Br J Dermatol 1988, 118:415-423.
66. Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1993, 306:555-556.
67. Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM Antibiotic resistant propionibacteria and acne: crisis or conundrum?. J Invest Dermatol 1997, 108:381.
68. Schafer F, Fich F, Lam M, Gárate C, Wozniak A, Garcia P Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acne. Int J Dermatol 2013, 52:418-425.
69. Mendoza N, Hernandez PO, Tyring SK, Haitz KA, Motta A Antimicrobial susceptibility of Propionibacterium acnes isolates from acne patients in Colombia. Int J Dermatol 2013, 52:688-692.
70. Luk NM, Hui M, Lee HC, et al. Antibiotic-resistant Propionibacterium acnes among acne patients in a regional skin centre in Hong Kong. J Eur Acad Dermatol Venereol 2013, 27:31-36.
71. Nakase K, Nakaminami H, Noguchi N, Nishijima S, Sasatsu M First report of high levels of clindamycin-resistant Propionibacterium acnes carrying erm(X) in Japanese patients with acne vulgaris. J Dermatol 2012, 39:794-796.
72. González R, Welsh O, Ocampo J, et al. In vitro antimicrobial susceptibility of Propionibacterium acnes isolated from acne patients in northern Mexico. Int J Dermatol 2010, 49:1003-1007.
73. Moon SH, Roh HS, Kim YH, Kim JE, Ko JY, Ro YS Antibiotic resistance of microbial strains isolated from Korean acne patients. J Dermatol 2012, 39:833-837.
74. Nakase K, Nakaminami H, Takenaka Y, Hayashi N, Kawashima M, Noguchi N Relationship between the severity of acne vulgaris and antimicrobial resistance of bacteria isolated from acne lesions in a hospital in Japan. J Med Microbiol 2014, 63:721-728.
75. Sardana K, Garg VK Antibiotic resistance in acne: is it time to look beyond antibiotics and Propionobacterium acnes?. Int J Dermatol 2014, 53:917-919.
76. Mills O, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002, 82:260-265.
77. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003, 139:467-471.
78. Margolis DJ, Bowe WP, Hoffstad O, Berlin JA Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005, 141:1132-1136.
79. Delyle LG, Vittecoq O, Bourdel A, Duparc F, Michot C, Le Loët X Chronic destructive oligoarthritis associated with Propionibacterium acnes in a female patient with acne vulgaris: septic-reactive arthritis?. Arthritis Rheum 2000, 43:2843-2847.
80. Aubin GG, Portillo ME, Trampuz A, Corvec S Propionibacterium acnes, an emerging pathogen: from acne to implant-infections, from phylotype to resistance. Med Mal Infect 2014, 44:241-250.
81. Kasimatis G, Fitz-Gibbon S, Tomida S, Wong M, Li H Analysis of complete genomes of Propionibacterium acnes reveals a novel plasmid and increased pseudogenes in an acne associated strain. Biomed Res Int 2013, 2013:918320.
82. Ross JI, Eady EA, Carnegie E, Cove JH Detection of transposon Tn5432-mediated macrolide-lincosamide-streptogramin B (MLSB) resistance in cutaneous propionibacteria from six European cities. J Antimicrob Chemother 2002, 49:165-168.
83. El-Mahdy TS, Abdalla S, El-Domany R, Mohamed MS, Ross JI, Snelling AM Detection of a new erm(X)-mediated antibiotic resistance in Egyptian cutaneous propionibacteria. Anaerobe 2010, 16:376-379.
84. Cunliffe WJ, Holland KT, Bojar R, Levy SF A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002, 24:1117-1133.
85. Humphrey S Antibiotic resistance in acne treatment. Skin Therapy Lett 2012, 17:1-3.
86. Simonart T, Dramaix M Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005, 153:395-403.
87. Kinney MA, Yentzer BA, Fleischer AB, Feldman SR Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance?. J Drugs Dermatol 2010, 9:519-524.
88. Christensen GJ, Brüggemann H Bacterial skin commensals and their role as host guardians. Benef Microbes 2014, 5:201-215.
89. Harkaway KS, McGinley KJ, Foglia AN, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 1992, 126:586-590.
90. Baird P, Hughes S, Sullivan M, Willmot I Penetration into bone and tissues of clindamycin phosphate. Postgrad Med J 1978, 54:65-67.
91. Kaplan SL Recent lessons for the management of bone and joint infections. J Infect 2014, 68(suppl 1):S51-S56.
92. Chon SY, Doan HQ, Mays RM, Singh SM, Gordon RA, Tyring SK Antibiotic overuse and resistance in dermatology. Dermatol Ther 2012, 25:55-69.
93. Margolis DJ, Fanelli M, Kupperman E, et al. Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study. Arch Dermatol 2012, 148:326-332.
94. Portillo ME, Corvec S, Borens O, Trampuz A Propionibacterium acnes: an underestimated pathogen in implant-associated infections. Biomed Res Int 2013, 2013:804391.
95. Tammelin A, Hambraeus A, Ståhle E Mediastinitis after cardiac surgery: improvement of bacteriological diagnosis by use of multiple tissue samples and strain typing. J Clin Microbiol 2002, 40:2936-2941.
96. Vanagt WY, Daenen WJ, Delhaas T Propionibacterium acnes endocarditis on an annuloplasty ring in an adolescent boy. Heart 2004, 90:e56.
97. Furustrand Tafin U, Trampuz A, Corvec S In vitro emergence of rifampicin resistance in Propionibacterium acnes and molecular characterization of mutations in the rpoB gene. J Antimicrob Chemother 2013, 68:523-528.
98. Del Rosso JQ, Kim GK Topical antibiotics: therapeutic value or ecologic mischief?. Dermatol Ther 2009, 22:398-406.
99. Leyden JJ, Preston N, Osborn C, Gottschalk RW In-vivo effectiveness of adapalene 0.1%/benzoyl peroxide 2.5% gel on antibiotic-sensitive and resistant Propionibacterium acnes. J Clin Aesthet Dermatol 2011, 4:22-26.
100. Williams HC, Dellavalle RP, Garner S Acne vulgaris. Lancet 2012, 379:361-372.
101. Dréno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004, 14:391-399.
102. Del Rosso JQ, Leyden JJ Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin 2007, 25:127-132.
103. Eady EA, Bojar RA, Jones CE, Cove JH, Holland KT, Cunliffe WJ The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996, 134:107-113.
104. Seidler EM, Kimball AB Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2·5% benzoyl peroxide and clindamycin topical treatments in acne. J Am Acad Dermatol 2011, 65:e117-e119.
105. Eady EA, Farmery MR, Ross JI, Cove JH, Cunliffe WJ Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol 1994, 131:331-336.
106. Leyden J, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol 2006, 142:605-612.
107. Gold LS, Cruz A, Eichenfield L, et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2·5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis 2010, 85:94-104.
108. Poulin Y, Sanchez NP, Bucko A, et al. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol 2011, 164:1376-1382.
109. BenzaClin full prescribing information Sanofi Aventis, (accessed Jan 10, 2016). http://medlibrary.org/lib/rx/meds/benzaclin-3/page/3/.
110. Jackson JM, Fu JJ, Almekinder JL A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/ clindamycin phosphate 1% gel compared with a clindamycin phosphate 1·2%/tretinoin 0·025% gel in the topical treatment of acne vulgaris. J Drugs Dermatol 2010, 9:131-136.
111. Restriction d'utilisation de la minocycline en raison d'un risque de syndromes d'hypersensibilité graves et d'atteintes auto-immunes. Information destinée aux prescripteurs et aux pharmaciens 2012, L'Agence Nationale de Sécurité du Médicament et Des Produits de Santé, L'Agence Nationale de Sécurité du Médicament et Des Produits de Santé, Paris.
112. Recommandations de bonne pratique. Traitement de l'acné par voie locale et générale 2008, L'Agence Nationale de Sécurité du Médicament et Des Produits de Santé, L'Agence Nationale de Sécurité du Médicament et Des Produits de Santé, Paris.
113. Campo MH, Zuluaga A, Escobar P, et al. Efficacy and safety comparison of lymecycline associated with adapalene and minocycline associated with adapalene in the treatment of acne vulgaris. 20th World Congress of Dermatology; Paris, France; July 1-5, 2002. P0005.
114. Tan J, Humphrey S, Vender R, et al. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol 2014, 171:1508-1516.
115. Fitz-Gibbon S, Tomida S, Chiu BH, et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol 2013, 133:2152-2160.
116. Chewapreecha C, Harris SR, Croucher NJ, et al. Dense genomic sampling identifies highways of pneumococcal recombination. Nat Genet 2014, 46:305-309.
117. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999, 140:672-676.
118. Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol 2011, 131:363-370.
119. Karciauskiene J, Valiukeviciene S, Gollnick H, Stang A The prevalence and risk factors of adolescent acne among schoolchildren in Lithuania: a cross-sectional study. J Eur Acad Dermatol Venereol 2014, 28:733-740.